Meeting
2015 Genitourinary Cancers Symposium
Sunitinib and pazopanib treatment patterns and cost outcomes in Medicare supplemental-covered patients with renal cell carcinoma.
Authors
James Harnett
Pfizer Inc., New York, NY
James Harnett , Elizabeth A. MacLean , Helen Bhattacharyya , Laura A. Cisar , Caroline Hoang , Jack Mardekian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 485)
DOI
10.1200/jco.2015.33.7_suppl.485
Abstract #
485
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.
First Author: Nicholas J. Vogelzang
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2017 Genitourinary Cancers Symposium
Determinants of treatment in patients with stage IV renal cell carcinoma.
First Author: Christopher S. Hollenbeak
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).
First Author: Lauren Caitlin Curry